{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T14:36:44Z","timestamp":1775659004050,"version":"3.50.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s10067-023-06709-2","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T11:01:47Z","timestamp":1691146907000},"page":"103-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study"],"prefix":"10.1007","volume":"43","author":[{"given":"Yinan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep K.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satabdi","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2310-901X","authenticated-orcid":false,"given":"Rajender R.","family":"Aparasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"issue":"7","key":"6709_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41584-020-0428-y","volume":"16","author":"AG Semb","year":"2020","unstructured":"Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S (2020) Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol 16(7):361\u2013379. https:\/\/doi.org\/10.1038\/s41584-020-0428-y","journal-title":"Nat Rev Rheumatol"},{"issue":"13","key":"6709_CR2","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. J Am Med Assoc 320(13):1360\u20131372. https:\/\/doi.org\/10.1001\/jama.2018.13103","journal-title":"J Am Med Assoc"},{"issue":"9","key":"6709_CR3","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00296-017-3726-1","volume":"37","author":"TM Hunter","year":"2017","unstructured":"Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB (2017) Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004\u20132014. Rheumatol Int 37(9):1551\u20131557. https:\/\/doi.org\/10.1007\/s00296-017-3726-1","journal-title":"Rheumatol Int"},{"issue":"7","key":"6709_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR et al (2021) 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 73(7):924\u2013939. https:\/\/doi.org\/10.1002\/acr.24596","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"6709_CR5","doi-asserted-by":"publisher","first-page":"S685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):S685\u2013S699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"6709_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/art.20853","volume":"52","author":"H Maradit-Kremers","year":"2005","unstructured":"Maradit-Kremers H, Crowson CS, Nicola PJ et al (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52(2):402\u2013411. https:\/\/doi.org\/10.1002\/art.20853","journal-title":"Arthritis Rheum"},{"issue":"9","key":"6709_CR7","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","volume":"107","author":"DH Solomon","year":"2003","unstructured":"Solomon DH, Karlson EW, Rimm EB et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107(9):1303\u20131307. https:\/\/doi.org\/10.1161\/01.CIR.0000054612.26458.B2","journal-title":"Circulation"},{"issue":"3","key":"6709_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/rheumatology\/kez371","volume":"59","author":"SA Provan","year":"2020","unstructured":"Provan SA, Lillegraven S, Sexton J et al (2020) Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study. Rheumatology (United Kingdom) 59(3):505\u2013512. https:\/\/doi.org\/10.1093\/rheumatology\/kez371","journal-title":"Rheumatology (United Kingdom)"},{"key":"6709_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.6084\/m9.figshare.11295608","volume":"7","author":"B DeMizio Laura","year":"2020","unstructured":"DeMizio Laura B, Geraldino-Pardilla DJ (2020) Autoimmunity and inflammation link to cardiovascular disease risk in rheumatoid arthritis. Rheumatol Ther 7:19\u201333. https:\/\/doi.org\/10.6084\/m9.figshare.11295608","journal-title":"Rheumatol Ther"},{"key":"6709_CR10","doi-asserted-by":"publisher","unstructured":"England BR, Thiele GM, Anderson DR, Mikuls TR (2018) Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ 361. https:\/\/doi.org\/10.1136\/bmj.k1036","DOI":"10.1136\/bmj.k1036"},{"issue":"3","key":"6709_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/annrheumdis-2017-211727","volume":"77","author":"JR Curtis","year":"2018","unstructured":"Curtis JR, Xie F, Chen L, Saag KG, Yun H, Muntner P (2018) Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis 77(3):386\u2013392. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211727","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6709_CR12","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/art.39098","volume":"67","author":"DH Solomon","year":"2015","unstructured":"Solomon DH, Reed GW, Kremer JM et al (2015) Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheum 67(6):1449\u20131455. https:\/\/doi.org\/10.1002\/art.39098","journal-title":"Arthritis Rheum"},{"key":"6709_CR13","doi-asserted-by":"publisher","unstructured":"Crowson CS, Liao KP, Davis JM et al (2013) Rheumatoid arthritis and cardiovascular disease. Am Heart J 166(4). https:\/\/doi.org\/10.1016\/j.ahj.2013.07.010","DOI":"10.1016\/j.ahj.2013.07.010"},{"issue":"5","key":"6709_CR14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41584-021-00593-3","volume":"17","author":"F Atzeni","year":"2021","unstructured":"Atzeni F, Rodr\u00edguez-Carrio J, Popa CD, Nurmohamed MT, Sz\u0171cs G, Szekanecz Z (2021) Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat Rev Rheumatol 17(5):270\u2013290. https:\/\/doi.org\/10.1038\/s41584-021-00593-3","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"6709_CR15","doi-asserted-by":"publisher","first-page":"e007393","DOI":"10.1161\/JAHA.117.007393","volume":"7","author":"EH Kang","year":"2018","unstructured":"Kang EH, Jin Y, Brill G et al (2018) Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort study. J Am Heart Assoc 7(3):e007393. https:\/\/doi.org\/10.1161\/JAHA.117.007393","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"6709_CR16","doi-asserted-by":"publisher","first-page":"e24579","DOI":"10.1097\/MD.0000000000024579","volume":"100","author":"KJ Sun","year":"2021","unstructured":"Sun KJ, Liu LL, Hu JH, Chen YY, Xu DY (2021) Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: an updated meta-analysis. Medicine 100(7):e24579. https:\/\/doi.org\/10.1097\/MD.0000000000024579","journal-title":"Medicine"},{"issue":"3","key":"6709_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T et al (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480\u2013489. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206624","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"6709_CR18","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/rheumatology\/keq316","volume":"50","author":"SL Westlake","year":"2011","unstructured":"Westlake SL, Colebatch AN, Baird J et al (2011) Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 50(3):518\u2013531. https:\/\/doi.org\/10.1093\/rheumatology\/keq316","journal-title":"Rheumatology"},{"issue":"3","key":"6709_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/1759720X11436239","volume":"4","author":"JL Marks","year":"2012","unstructured":"Marks JL, Edwards CJ (2012) Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity. Ther Adv Musculoskelet Dis 4(3):149\u2013157. https:\/\/doi.org\/10.1177\/1759720X11436239","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"10","key":"6709_CR20","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","volume":"75","author":"C Gabay","year":"2016","unstructured":"Gabay C, Mcinnes IB, Kavanaugh A et al (2016) Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 75(10):1806\u20131812. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207872","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"6709_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/acr.23875","volume":"72","author":"S Singh","year":"2020","unstructured":"Singh S, Fumery M, Singh AG et al (2020) Comparative risk of cardiovascular events with biologic and synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 72(4):561\u2013576","journal-title":"Arthritis Care Res"},{"issue":"4","key":"6709_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/nejmoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316\u2013326. https:\/\/doi.org\/10.1056\/nejmoa2109927","journal-title":"N Engl J Med"},{"key":"6709_CR23","unstructured":"FDA, CDER. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions.  https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed 28 Nov 2022"},{"issue":"6","key":"6709_CR24","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3899\/jrheum.191326","volume":"48","author":"F Xie","year":"2021","unstructured":"Xie F, Chen L, Yun H, Levitan EB, Curtis JR (2021) Benefits of methotrexate use on cardiovascular disease risk among rheumatoid arthritis patients initiating biologic disease-modifying antirheumatic drugs. J Rheumatol 48(6):804\u2013812. https:\/\/doi.org\/10.3899\/jrheum.191326","journal-title":"J Rheumatol"},{"key":"6709_CR25","unstructured":"IBM MarketScan Research Databases for Life Sciences Researchers.\u00a0http:\/\/kff.org\/other\/state-indicator\/total-. Accessed 28 Nov 2022"},{"issue":"4","key":"6709_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0002-8703(03)00512-X","volume":"146","author":"V Essebag","year":"2003","unstructured":"Essebag V, Genest J, Suissa S, Pilote L (2003) The nested case-control study in cardiology. Am Heart J 146(4):581\u2013590. https:\/\/doi.org\/10.1016\/S0002-8703(03)00512-X","journal-title":"Am Heart J"},{"issue":"9","key":"6709_CR27","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3899\/jrheum.170926","volume":"45","author":"Y Jin","year":"2018","unstructured":"Jin Y, Kang EH, Brill G, Desai RJ, Kim SC (2018) Cardiovascular (CV) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease. J Rheumatol 45(9):1240\u20131248. https:\/\/doi.org\/10.3899\/jrheum.170926","journal-title":"J Rheumatol"},{"issue":"3","key":"6709_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.semarthrit.2018.03.012","volume":"48","author":"SC Kim","year":"2018","unstructured":"Kim SC, Solomon DH, Rogers JR et al (2018) No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: a multi-database cohort study. Semin Arthritis Rheum 48(3):399\u2013405. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.03.012","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"6709_CR29","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/rheumatology\/keh610","volume":"44","author":"S Bernatsky","year":"2005","unstructured":"Bernatsky S, Hudson M, Suissa S (2005) Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology 44(5):677\u2013680. https:\/\/doi.org\/10.1093\/rheumatology\/keh610","journal-title":"Rheumatology"},{"issue":"1","key":"6709_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/rheumatology\/keab294","volume":"61","author":"RJ Desai","year":"2022","unstructured":"Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC (2022) Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (United Kingdom) 61(1):121\u2013130. https:\/\/doi.org\/10.1093\/rheumatology\/keab294","journal-title":"Rheumatology (United Kingdom)"},{"issue":"11","key":"6709_CR31","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.3899\/jrheum.131464","volume":"41","author":"RJ Desai","year":"2014","unstructured":"Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski M, Farley J (2014) Tumor necrosis factor-\u03b1 inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study. J Rheumatol 41(11):2129\u20132136. https:\/\/doi.org\/10.3899\/jrheum.131464","journal-title":"J Rheumatol"},{"issue":"9","key":"6709_CR32","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3899\/jrheum.170926","volume":"45","author":"Y Jin","year":"2018","unstructured":"Jin Y, Kang EH, Brill G, Desai RJ, Kim SC (2018) Cardiovascular (CV) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease. J Rheumatol 45(9):1240\u20131248. https:\/\/doi.org\/10.3899\/jrheum.170926","journal-title":"J Rheumatol"},{"issue":"3","key":"6709_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/acr.22944","volume":"69","author":"BC Sauer","year":"2017","unstructured":"Sauer BC, Teng CC, Tang D et al (2017) Persistence with conventional triple therapy versus a tumor necrosis factor inhibitor and methotrexate in US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 69(3):313\u2013322. https:\/\/doi.org\/10.1002\/acr.22944","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"6709_CR34","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/acr.22638","volume":"67","author":"M Bonafede","year":"2015","unstructured":"Bonafede M, Johnson BH, Tang DH, Shah N, Harrison DJ, Collier DH (2015) Etanercept-methotrexate combination therapy initiators have greater adherence and persistence than triple therapy initiators with rheumatoid arthritis. Arthritis Care Res (Hoboken) 67(12):1656\u20131663. https:\/\/doi.org\/10.1002\/acr.22638","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"6709_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2482","volume":"10","author":"G Ting","year":"2008","unstructured":"Ting G, Schneeweiss S, Scranton R et al (2008) Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther 10(4):1\u20139. https:\/\/doi.org\/10.1186\/ar2482","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"6709_CR36","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1007\/s11999-014-3686-7","volume":"472","author":"ME Menendez","year":"2014","unstructured":"Menendez ME, Neuhaus V, van Dijk CN, Ring D (2014) The Elixhauser comorbidity method outperforms the Charlson index in predicting inpatient death after orthopaedic surgery. Clin Orthop Relat Res 472(9):2878\u20132886. https:\/\/doi.org\/10.1007\/s11999-014-3686-7","journal-title":"Clin Orthop Relat Res"},{"issue":"6","key":"6709_CR37","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2013-204011","volume":"74","author":"H Yun","year":"2015","unstructured":"Yun H, Xie F, Delzell E et al (2015) Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis 74(6):1065\u20131071. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6709_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13075-021-02655-z","volume":"24","author":"M Meehan","year":"2022","unstructured":"Meehan M, Shah A, Lobo J et al (2022) Validation of an algorithm to identify incident interstitial lung disease in patients with rheumatoid arthritis. Arthritis Res Ther 24(1):2. https:\/\/doi.org\/10.1186\/s13075-021-02655-z","journal-title":"Arthritis Res Ther"},{"key":"6709_CR39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2147\/JPR.S82566","volume":"8","author":"B Emir","year":"2015","unstructured":"Emir B, Masters ET, Mardekian J, Clair A, Kuhn M, Silverman SL (2015) Identification of a potential fibromyalgia diagnosis using random forest modeling applied to electronic medical records. J Pain Res 8:277\u2013288. https:\/\/doi.org\/10.2147\/JPR.S82566","journal-title":"J Pain Res"},{"issue":"2","key":"6709_CR40","doi-asserted-by":"publisher","first-page":"e0117952","DOI":"10.1371\/journal.pone.0117952","volume":"10","author":"LR Baghdadi","year":"2015","unstructured":"Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA (2015) The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PloS One 10(2):e0117952. https:\/\/doi.org\/10.1371\/journal.pone.0117952","journal-title":"PloS One"},{"key":"6709_CR41","unstructured":"FDA. HUMIRA\u00ae (adalimumab) injection for subcutaneous use.\u00a0www.fda.gov\/medwatch.\u00a0Accessed 28 Nov 2022"},{"issue":"4","key":"6709_CR42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/acr.23875","volume":"72","author":"S Singh","year":"2020","unstructured":"Singh S, Fumery M, Singh AG et al (2020) Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 72(4):561\u2013576. https:\/\/doi.org\/10.1002\/acr.23875","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"6709_CR43","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3899\/jrheum.200265","volume":"48","author":"G Ozen","year":"2021","unstructured":"Ozen G, Pedro S, Michaud K (2021) The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 48(5):648\u2013655. https:\/\/doi.org\/10.3899\/jrheum.200265","journal-title":"J Rheumatol"},{"issue":"6","key":"6709_CR44","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/art.37916","volume":"65","author":"I Navarro-Mill\u00e1n","year":"2013","unstructured":"Navarro-Mill\u00e1n I, Charles-Schoeman C, Yang S et al (2013) Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum 65(6):1430\u20131438. https:\/\/doi.org\/10.1002\/art.37916","journal-title":"Arthritis Rheum"},{"issue":"1","key":"6709_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/art.39833","volume":"69","author":"C Charles-Schoeman","year":"2017","unstructured":"Charles-Schoeman C, Yin Lee Y, Shahbazian A et al (2017) Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial. Arthritis Rheum 69(1):46\u201357. https:\/\/doi.org\/10.1002\/art.39833","journal-title":"Arthritis Rheum"},{"issue":"6","key":"6709_CR46","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/acr2.11256","volume":"3","author":"JT Giles","year":"2021","unstructured":"Giles JT, Rist PM, Liao KP et al (2021) Testing the effects of disease-modifying antirheumatic drugs on vascular inflammation in rheumatoid arthritis: rationale and design of the TARGET trial. ACR Open Rheumatol 3(6):371\u2013380. https:\/\/doi.org\/10.1002\/acr2.11256","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"6709_CR47","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/art.39502","volume":"68","author":"C Charles\u2010Schoeman","year":"2016","unstructured":"Charles\u2010Schoeman C, Wang X, Lee YY, Shahbazian A, Navarro\u2010Mill\u00e1n I, Yang S, Chen L, Cofield SS, Moreland LW, O'Dell J, Bathon JM (2016) Association of triple therapy with improvement in cholesterol profiles over two-year follow-up in the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum 68(3):577\u2013586","journal-title":"Arthritis Rheum"},{"issue":"4","key":"6709_CR48","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1136\/ard.2010.129916","volume":"70","author":"JD Greenberg","year":"2011","unstructured":"Greenberg JD, Kremer JM, Curtis JR et al (2011) Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 70(4):576\u2013582. https:\/\/doi.org\/10.1136\/ard.2010.129916","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"6709_CR49","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/acr.22166","volume":"66","author":"A Bili","year":"2014","unstructured":"Bili A, Tang X, Pranesh S et al (2014) Tumor necrosis factor \u03b1 inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 66(3):355\u2013363. https:\/\/doi.org\/10.1002\/acr.22166","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"6709_CR50","first-page":"1213","volume":"32","author":"LTH Jacobsson","year":"2005","unstructured":"Jacobsson LTH, Turesson C, G\u00fclfe A et al (2005) Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32(7):1213\u20131218","journal-title":"J Rheumatol"},{"issue":"8","key":"6709_CR51","doi-asserted-by":"publisher","first-page":"730.e9","DOI":"10.1016\/j.amjmed.2013.02.016","volume":"126","author":"DH Solomon","year":"2013","unstructured":"Solomon DH, Curtis JR, Saag KG et al (2013) Cardiovascular risk in rheumatoid arthritis: comparing TNF-\u03b1 blockade with nonbiologic DMARDs. Am J Med 126(8):730.e9\u2013730.e17. https:\/\/doi.org\/10.1016\/j.amjmed.2013.02.016","journal-title":"Am J Med"},{"issue":"4","key":"6709_CR52","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2016-209784","volume":"76","author":"ASL Low","year":"2017","unstructured":"Low ASL, Symmons DPM, Lunt M et al (2017) Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 76(4):654\u2013660. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209784","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6709_CR53","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-016-1077-z","volume":"18","author":"Y Meissner","year":"2016","unstructured":"Meissner Y, Zink A, Kekow J et al (2016) Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Res Ther 18(1):183. https:\/\/doi.org\/10.1186\/s13075-016-1077-z","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"6709_CR54","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1136\/annrheumdis-2020-217653","volume":"79","author":"S Plein","year":"2020","unstructured":"Plein S, Erhayiem B, Fent G et al (2020) Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-na\u00efve, early rheumatoid arthritis. Ann Rheum Dis 79(11):1414\u20131422. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217653","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"6709_CR55","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1002\/art.22809","volume":"56","author":"WG Dixon","year":"2007","unstructured":"Dixon WG, Watson KD, Lunt M et al (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor \u03b1 therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56(9):2905\u20132912. https:\/\/doi.org\/10.1002\/art.22809","journal-title":"Arthritis Rheum"},{"issue":"12","key":"6709_CR56","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1136\/annrheumdis-2015-208995","volume":"75","author":"L Ljung","year":"2016","unstructured":"Ljung L, Rantap\u00e4\u00e4-Dahlqvist S, Jacobsson LTH et al (2016) Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann Rheum Dis 75(12):2087\u20132094. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208995","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"6709_CR57","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ahj.2008.02.025","volume":"156","author":"S Setoguchi","year":"2008","unstructured":"Setoguchi S, Schneeweiss S, Avorn J et al (2008) Tumor necrosis factor-\u03b1 antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 156(2):336\u2013341. https:\/\/doi.org\/10.1016\/j.ahj.2008.02.025","journal-title":"Am Heart J"},{"issue":"8","key":"6709_CR58","doi-asserted-by":"publisher","first-page":"e0220178","DOI":"10.1371\/journal.pone.0220178","volume":"14","author":"B Castagn\u00e9","year":"2019","unstructured":"Castagn\u00e9 B, Viprey M, Martin J, Schott AM, Cucherat M, Soubrier M (2019) Cardiovascular safety of tocilizumab: a systematic review and network meta-analysis. PloS One 14(8):e0220178. https:\/\/doi.org\/10.1371\/journal.pone.0220178","journal-title":"PloS One"},{"issue":"1","key":"6709_CR59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/art.41095","volume":"72","author":"JT Giles","year":"2020","unstructured":"Giles JT, Sattar N, Gabriel S et al (2020) Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum 72(1):31\u201340. https:\/\/doi.org\/10.1002\/art.41095","journal-title":"Arthritis Rheum"},{"issue":"6","key":"6709_CR60","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/art.40084","volume":"69","author":"SC Kim","year":"2017","unstructured":"Kim SC, Solomon DH, Rogers JR et al (2017) Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study. Arthritis Rheum 69(6):1154\u20131164. https:\/\/doi.org\/10.1002\/art.40084","journal-title":"Arthritis Rheum"},{"issue":"10","key":"6709_CR61","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1136\/annrheumdis-2015-207870","volume":"75","author":"J Zhang","year":"2016","unstructured":"Zhang J, Xie F, Yun H et al (2016) Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 75(10):1813\u20131818. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207870","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"6709_CR62","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/acr.23737","volume":"71","author":"F Xie","year":"2019","unstructured":"Xie F, Yun H, Levitan EB, Muntner P, Curtis JR (2019) Tocilizumab and the risk of cardiovascular disease: direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 71(8):1004\u20131018. https:\/\/doi.org\/10.1002\/acr.23737","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6709_CR63","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S0140","volume":"379","author":"N Sarwar","year":"2012","unstructured":"Sarwar N, Adam D, Butterworth S (2012) Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies IL6R Genetics Consortium and Emerging Risk Factors Collaboration*. The Lancet 379:1205\u20131213. https:\/\/doi.org\/10.1016\/S0140","journal-title":"The Lancet"},{"key":"6709_CR64","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.vph.2016.01.006","volume":"81","author":"GW Naerr","year":"2016","unstructured":"Naerr GW, Rein P, Saely CH, Drexel H (2016) Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis. Vascul Pharmacol 81:22\u201330. https:\/\/doi.org\/10.1016\/j.vph.2016.01.006","journal-title":"Vascul Pharmacol"},{"key":"6709_CR65","doi-asserted-by":"publisher","first-page":"105689","DOI":"10.1016\/j.phrs.2021.105689","volume":"169","author":"G Reyes-Soffer","year":"2021","unstructured":"Reyes-Soffer G, Westerterp M (2021) Beyond lipoprotein(a) plasma measurements: lipoprotein(a) and inflammation. Pharmacol Res 169:105689. https:\/\/doi.org\/10.1016\/j.phrs.2021.105689","journal-title":"Pharmacol Res"},{"issue":"10","key":"6709_CR66","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1136\/annrheumdis-2013-203617","volume":"73","author":"GA Karpouzas","year":"2014","unstructured":"Karpouzas GA, Malpeso J, Choi TY, Li D, Munoz S, Budoff MJ (2014) Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann Rheum Dis 73(10):1797\u20131804. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203617","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6709_CR67","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/art.39098","volume":"67","author":"DH Solomon","year":"2015","unstructured":"Solomon DH, Reed GW, Kremer JM et al (2015) Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheum 67(6):1449\u20131455. https:\/\/doi.org\/10.1002\/art.39098","journal-title":"Arthritis Rheum"},{"issue":"7","key":"6709_CR68","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41584-020-0428-y","volume":"16","author":"AG Semb","year":"2020","unstructured":"Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S (2020) Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol 16(7):361\u2013379. https:\/\/doi.org\/10.1038\/s41584-020-0428-y","journal-title":"Nat Rev Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06709-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06709-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06709-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T15:06:40Z","timestamp":1704726400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06709-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["6709"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06709-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The University of Houston\u2019s Institutional Review Board approved the study protocol under the exempt category. Informed consent is not required as the MarketScan claims are based on de-identified medical information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This research did not receive any grant from funding agencies in the public, commercial, or not-for-profit sectors. Dr. Rajender R. Aparasu reports grants from Astellas, Incyte, and Novartis, outside the submitted work. The other authors have no personal or financial conflicts of interest to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}